IMDX expects to submit FDA response before Jan. 21, 2027 deadline as it targets $800M U.S. kitted transplant testing market
Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q3 2026
Management View
“Today, I will focus on 2 main topics: start of U.S. revenue from GraftAssure and what we believe will be the final steps related to our FDA submission.” (President, CEO & Director Joshua Riggs)
Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.